Home
Team
Technology
Investors
Pipeline
Contact Us

Helix BioPharma 2012 Annual Report

Home
Helix BioPharma 2012 Annual Report

12/09/201321/10/2023
admin
0 Comments
FY2014

Helix BioPharma 2012 Annual Report

Download the PDF

Post navigation

Previous: Helix BioPharma Corp. to Conduct Interim Review of its LDOS002 Phase I/II Clinical Study

Helix Biopharma Corp. Initiates Enrollment for Fifth Cohort in Polish Phase I/II Clinical Study of its Lung Cancer Drug Candidate L-DOS47:Next

Search for:

Recent Posts

Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Gemcitabine Chemotherapy Compound
Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor and Expand Immune-Oncology Portfolio
Helix Biopharma Corp. Announces Issuance of U.S. Patent
Helix Biopharma Corp. Enters into Non-Binding Letter of Intent to Acquire Laevoroc Group’s Oncology Assets
Helix BioPharma Corp. Attends World ADC San Diego

Recent Stories

Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Gemcitabine Chemotherapy Compound Dec 02, 2024
Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor and Expand Immune-Oncology Portfolio Nov 29, 2024
Helix Biopharma Corp. Announces Issuance of U.S. Patent Nov 21, 2024
Helix Biopharma Corp. Enters into Non-Binding Letter of Intent to Acquire Laevoroc Group’s Oncology Assets Nov 13, 2024
Helix BioPharma Corp. Attends World ADC San Diego Nov 11, 2024

Quick Links

Team
Technology
Pipeline
News
Investors
Contact Us

Other Links

Privacy Policy
Cookie Policy
Sedar Filings
ClinicalTrials.gov

Get In Touch

Bay Adelaide Centre - North Tower 40 Temperance Street, Suite 2700 Toronto, ON M5H 0B4
helix@helixbiopharma.com
+1 604 684 2181
Mon-Fri: 9.00am To 5.00pm

Copyright © 2024 All Rights Reserved | Helix biopharma